Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report.
Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, Chakrabarty T, Frey BN, Milev RV, Müller DJ, Parikh SV, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Morton E, et al. Among authors: lou w. Pharmacopsychiatry. 2021 Sep;54(5):225-231. doi: 10.1055/a-1385-0263. Epub 2021 Mar 2. Pharmacopsychiatry. 2021. PMID: 33652477
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, McInerney S, Chakrabarty T, Frey BN, Milev RV, Müller DJ, Parikh SV, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Morton E, et al. Among authors: lou w. CNS Drugs. 2021 Apr;35(4):439-450. doi: 10.1007/s40263-021-00803-2. Epub 2021 Apr 16. CNS Drugs. 2021. PMID: 33860922
Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report.
Khoo Y, Demchenko I, Frey BN, Milev RV, Ravindran AV, Parikh SV, Ho K, Rotzinger S, Lou W, Lam RW, Kennedy SH, Bhat V; CAN-BIND Investigator Team. Khoo Y, et al. Among authors: lou w. J Affect Disord. 2022 Mar 1;300:50-58. doi: 10.1016/j.jad.2021.12.027. Epub 2021 Dec 15. J Affect Disord. 2022. PMID: 34921820
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Espinola CW, Khoo Y, Parmar R, Demchenko I, Frey BN, Milev RV, Ravindran AV, Parikh SV, Ho K, Rotzinger S, Lou W, Lam RW, Kennedy SH, Bhat V; CAN-BIND Investigator Team. Espinola CW, et al. Among authors: lou w. Brain Behav. 2022 May;12(5):e2555. doi: 10.1002/brb3.2555. Epub 2022 Mar 25. Brain Behav. 2022. PMID: 35333448 Free PMC article.
Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Diep C, Rosenek N, Khoo Y, Gandhi W, van Reekum CM, Ravindran AV, Ladha KS, Frey BN, Milev RV, Rotzinger S, Lam RW, Kennedy SH, Lou W, Salomons T, Bhat V. Diep C, et al. Among authors: lou w. Psychiatry Res. 2022 Jun;312:114557. doi: 10.1016/j.psychres.2022.114557. Epub 2022 Apr 16. Psychiatry Res. 2022. PMID: 35461118 Clinical Trial.
1,228 results